Jia Ruan, M.D., Ph.D.

Medical Oncology

Publications

Original Research

Ruan, J., Xie, Q-w., Hutchinson, N., Cho, H., Wolfe, G. C., and Nathan, C. (1996) Inducible Nitric Oxide Synthase Requires Both the Canonical Calmodulin-binding Domain and Additional Sequences in Order to Bind Calmodulin and Produce Nitric Oxide in the Absence of Free Ca. J. Biol. Chem. 271:22679-86.

Shiloh, M. U., Ruan, J., and Nathan, C. (1997) Evaluation of Bacterial Survival and Phagocytes Function with a Fluorescence-Based Microplate Assay. Infect. Immun. 65:3193-98.

Ehrt, S., Shiloh, M. U., Ruan, J., Choi, M., Gunzburg, S., Nathan, C., Xie, Q.-w., and Riley, L. W. (1997) An Antioxidant Gene from Mycobacterium tuberculosis. J. Exp. Med. 186: 1885-96.

Ruan, J., St John, G., Ehrt, S., Riley, L., Nathan, C. (1999) noxR3, a Novel Gene from Mycobacterium tuberculosis, Protects Salmonella typhimurium from Nitrosative and Oxidative Stress. Infect. Immun. 67:3276-83.

St John, G., Brot, N., Ruan, J., Erdjument-Bromage, H., Tempst, P., Weissbach, H., Nathan, C. (2001) Peptide Methionine Sulfoxide Reductase from Escherichia coli and Mycobacterium tuberculosis Protects Bacteria against Oxidative Damage from Reactive Nitrogen Intermediates. Proc Natl Acad Sci U S A 98(17):9901-6.

Gotlib, J., Berubé, C., Growney, J. D., Chen, C.-C., George, T. I., Williams, C., Kajiguchi, T., Ruan, J., Lilleberg, S. L., Durocher, J. A., Lichy, J. H., Wang, Y., Cohen, P. S., Arber, D., Heinrich, M. C., Neckers, L., Galli, S. J., Gilliland, D. G., and Coutré, S. E. (2005) Activity of the Tyrosine Kinase Inhibitor PKC412 in a Patient with Mast Cell Leukemia with the D816V KIT Mutation. Blood. 106(8):2865-70.

Ruan, J., Hyjek, E., Kermani, P., Christos, P.J., Ikalowych, S., Coleman, M., Hempstead, B., Leonard, J.P., Chadburn, A. and Rafii, S. (2006) Magnitude of Stromal Hemangiogenesis Correlates with Histologic Subtype of Non-Hodgkin#146;s Lymphoma. Clin Cancer Res. 12(19):5622-31

Coleman, M., Martin, P., Ruan, J., et al. (2008) Low Dose Metronomic Multidrug Therapy with the PEPC (Prednisone, Etoposide, Procarbazine, and Cyclophosphamide) Oral Combination Chemotherapy Regimen for Mantle Cell Lymphoma. Leukemia & Lymphoma. 49(3):447-50.

Coleman, M., Martin, P., Ruan, J., et al (2008) The PEP-C (Prednisone, Etoposide, Procarbazine, and Cyclophosphamide) Oral Combination Chemotherapy Regimen for Relapsing Refractory Lymphoma: Low Dose Metronomic, Multidrug Therapy. Cancer. 112(10):2228-32.

Martin, P., Chadburn, A., Christos, P., Furman, R., Ruan, J., Joyce, M. A., Fusco, E., Glynn, P., Elstrom, R., Niesvizky, R., Feldman, E. J., Shore, T. B., Schuster, M. W., Ely, S., Knowles, D. M., Chen-Kiang, S., Coleman, M., Leonard, J. P. (2008) Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Annals of Oncology. 19(7):1327-30.

Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R.R., Ruan, J., Elstrom, R., Niesvizky, R., Ely, S., Diliberto, M., Melnick, A., Knowles, D.M., Chen-Kiang, S., Coleman, M., Leonard, J.P. (2009) Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 27(8):1209-13.

Ruan, J., Martin, P., Coleman, M., Furman, R., Faye, A., Cheung, K., Elstrom, R., Lachs, M., Hajjar, K. A., Leonard, J. P. (2010) Durable responses with the metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma. Cancer. 116(11):2655-64.

Furman, R.R., Martin, P., Ruan, J., Cheung, Y.K., Vose, J.M., LaCasce, A.S., Elstrom, R., Coleman, M., Leonard, J.P. (2010) Phase I trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 116(23):5432-9.

Ruan, J., Martin, P., Furman, R.R., Lee, S.M., Cheung, K., Vose, J.M., LaCasce, A., Morrison, J., Elstrom, R., Ely, S., Chadburn, A., Cesarman, E., Coleman, M., Leonard, J.P. (2011) Bortezomib plus CHOP-Rituximab for previously untreated diffuse large B-Cell lymphoma and mantle cell lymphoma. J Clin Oncol. 29(6):690-7.

Review Articles

Leonard, J. P., Furman, R. R., Ruan, J., Coleman, M. (2005) New Developments in Immunotherapy for Non-Hodgkin's Lymphoma. Current Oncology Reports. 7(5):364-71.

Ruan, J. and Leonard, J. P. (2006) Mantle cell lymphoma: Current Concepts in Biology and Treatment. Cancer Treatment and Research. 131:141-59.

Leonard, J.P., Ruan, J., Martin, P., Coleman, M., Furman, R.R. (2007) New Agents in Development for Non-Hodgkin's Lymphoma. Seminars in Hematology. 44:S18-21.

Martin, P., Furman, R. R., Ruan, J., Elstrom, R., Barrientos, J., Niesvizky, R., Coleman, M., Leonard, J. P. (2008) Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Seminars in Hematology. 45(2):126-32.

Leonard, J. P., Martin, P., Ruan, J., Elstrom, R., Barrientos, J., Coleman, M., Furman, R. R. (2008) New monoclonal antibodies for non-Hodgkin's lymphoma. Annals of Oncology. Suppl 4:iv60-2.

Ruan, J., Hajjar, K. A., Rafii, S., Leonard, J. P. (2009) Angiogenesis and anti-angiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol. 20(3):413-24.

Ruan, J., Leonard, J.P. (2009) Targeting angiogenesis: a novel, rational therapeutic approach for non-Hodgkin lymphoma. Leuk Lymphoma. 50(5):679-81.

Ruan, J., Coleman, M., Leonard, J.P. (2009) Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology. 23(8): 683-90.

Book Chapter

Ruan, J. and Hajjar, H.A. Fibrinolysis and Thrombolysis, Chapter 136, Williams Hematology 8th edition, 2010.

Meeting Abstracts

Ruan, J., Q-w. Xie, N. Hutchinson, H. Cho, G. C. Wolfe, and C. Nathan. Calmodulin (CaM) binding region of mouse nitric oxide synthase-2 (residues 503-532) is necessary but not sufficient for CaM binding and nitric oxide production at trace calcium. American Society for Biochemistry and Molecular Biology Meeting, New Orleans, LA., June 2-6, 1996 (poster presentation).

Ruan, J., S. Ehrt, M. Shiloh, Q.-w. Xie, L. Riley, and C. Nathan. Anti-oxidant/anti-nitrosative gene from Mycobacterium tuberculosis: functional characterization in E. coli and S. typhimurium. The 5th International Meeting on Biology of Nitric Oxide. Kyoto, Japan, September 15-19, 1997 (podium presentation).

Gotlib, J., Berube, C., Ruan, J., Growney, J., Dugan, K., Falkow, R., Rosamilia, M., Resta, D., Cohen, P., Fabbro, D., Heinrich, M., Gilliland, D.G., Coutre, S. PKC412, inhibitor of the KIT tyrosine kinase, demonstrates efficacy in mast cell leukemia with the D816V KIT mutation. American Society of Hematology Annual Meeting, San Diego, CA, December 6-9, 2003 (poster presentation).

Ruan, J., Hyjek, E., Hooper, A.T., Vincent, L., Kermani, P., Christos, P.J., Ikalowych, S., Coleman, M., Hempstead, B., Leonard, J.P., Chadburn, A. and Rafii, S. Magnitude of Stromal Incorporation of VEGFR-1 , CD68 and alpha-SMA Hemangiogenic Cells Distinguishes Histologic Subtypes of Non-Hodgkin#146;s Lymphoma. American Society of Hematology Annual Meeting, Atlanta, GA, December 10-13, 2005 (poster presentation).

Ruan, J., Coleman, M., Furman, R.R., Glynn, P., Joyce, M., Ketas, J., Cheung, K., Church, S., Shore, T., Feldman, E.J., Rutherford, S.C., Hyjek, E., Chadburn, A., Rafii, S., and Leonard, J.P. Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease. American Society of Hematology Annual Meeting, Orlando, FL, December 9-12, 2006 (poster presentation).

Hajjar, K.A., Ruan, J., Sui, G., Deora, A.B., Church, S., Cohen-Gould, L., Rafii, S., Lyden, D.C., Ling, Q. Annexin 2 Mediates Plasminogen-Related Recruitment of Neovascular Mural Cells in Lymphoma Angiogenesis. American Society of Hematology Annual Meeting, Atlanta, GA, December 8-11, 2007 (poster presentation)

Ruan, J., Coleman, M., Furman, R. R., Martin, P., Glynn, P., Joyce, M., Goodwin, J., Cheung, K., Feldman, E., Schuster, M., Shore, T., Leonard, J. P. Durable responses with the anti-angiogenic metronomic regimen RT-PEPC in recurrent mantle cell lymphoma (MCL). Lugano lymphoma meeting, Lugano, Switzerland, June 2008.

Ruan, J., Martin, P., Coleman, M., Furman, R., Glynn, P., Joyce, M., Cheung, K., Shore, T., Schuster, M., Leonard, J. Durable Responses with the Anti-Angiogenic Metronomic Regimen RT-PEPC in Elderly Patients with Recurrent Mantle Cell Lymphoma (MCL). American Society of Clinical Oncology Annual Meeting, Orlando, FL, 2009 (Abs 8525)

Ruan, J., Martin, P., Furman, R.R., Vose, J.M., LaCasce, A., Cheung, Y.K., O'Loughlin, J., Elstrom, R., Niesvizky, R., Chadburn, A., Ely, S., Cesarman, E., Coleman, M., Leonard, J.P. CHOP-R Bortezomib as initial therapy for mantle cell lymphoma (MCL). American Society of Hematology Annual Meeting. New Orleans, LA 2009.

Ruan, J., Ward, M., Fan, L., Faye, A., Lane, M., Hajjar, K., Tyrell, L., Martin, P., Elstrom, R., Coleman, M., Furman, R.R., and Leonard, J.P. Levels of circulating endothelial cells and endothelial progenitors correlate with disease status and treatment response in human lymphoma subtypes of CLL and MCL. American Society of Hematology Annual Meeting. New Orleans, LA 2009.

Ruan, J., Mark, T., Allan, J., Morrison, J., Koirala, A., Martin, P., Coleman, C., Lachs, M., Niesvizky, R., Leonard, J.P. Elderly patients with lymphoma and myeloma can effectively participate in clinical trials of novel agents. American Society of Clinical Oncology Annual Meeting. Chicago, IL 2010.

Back to topBack To Top